title: Mechanisms of Resistance to Chemotherapy in Gastric Cancer.
abstract: Although surgical resection is the standard curative therapy for gastric cancer, these tumors are often diagnosed at an advanced stage, when surgery is not recommended. Alternative treatments such as radiotherapy and chemotherapy achieve only very modest results. There is therefore an urgent need to advance in this field of oncologic gastroenterology. The poor response of gastric cancer to chemotherapy is usually due to a combination of mechanisms of chemoresistance (MOC), which may include a reduction in drug uptake (MOC-1a), enhanced drug efflux (MOC-1b), a reduced proportion of active agents in tumor cells due to a reduction in pro-drug activation or an enhancement in drug inactivation (MOC-2), changes in the expression/function of the molecular targets of anticancer drugs (MOC-3), an enhanced ability of cancer cells to repair anticancer drug-induced DNA damage (MOC-4), and decreased expression/function of pro-apoptotic factors or up-regulation of anti-apoptotic genes (MOC-5). Two major goals of modern pharmacology aimed at overcoming this situation are the prediction of a lack of response to chemotherapy and the identification of the underlying mechanisms accounting for primary or acquired refractoriness to anticancer drugs. These are important issues if we are to select the best pharmacological regime for each patient and develop novel strategies to overcome chemoresistance. The present review reports updated information regarding the mechanisms of chemoresistance (from MOC-1 to MOC-5) in gastric cancer, the advances made in the prediction of the failure of chemotherapeutic treatment, and novel strategies based on gene therapy currently being developed to treat these tumors.
authors.forename: J J G
authors.initials: JJ
authors.lastname: Marin
authors.forename: R
authors.initials: R
authors.lastname: Al-Abdulla
authors.forename: E
authors.initials: E
authors.lastname: Lozano
authors.forename: O
authors.initials: O
authors.lastname: Briz
authors.forename: L
authors.initials: L
authors.lastname: Bujanda
authors.forename: J M
authors.initials: JM
authors.lastname: Banales
authors.affiliation: Department of Physiology and Pharmacology, Campus Miguel de Unamuno E.I.D. B-17, 37007- Salamanca, Spain. rociorm@usal.es.
authors.forename: R I R
authors.initials: RI
authors.lastname: Macias
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D043182:Carboxylesterase / Q000235:genetics / Q000378:metabolism; D065637:Cytochrome P-450 CYP2A6 / Q000235:genetics / Q000378:metabolism*; D004260:DNA Repair / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D015316:Genetic Therapy; D006801:Humans; D035683:MicroRNAs / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D029365:Organic Anion Transporters, ATP-Dependent / Q000235:genetics / Q000378:metabolism*; D027701:Organic Cation Transport Proteins / Q000235:genetics / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D035683:MicroRNAs; D029365:Organic Anion Transporters, ATP-Dependent; D027701:Organic Cation Transport Proteins; D065637:Cytochrome P-450 CYP2A6; D043182:Carboxylesterase